Innoviva, Inc. (INVA) Stock Analysis
Last updated Oct 27, 2026
Published Opportunity
This stock was published as a Compound Radar opportunity on Oct 5, 2026. Performance is tracked publicly from the original signal.
Health Check
Last analyzed Oct 23, 2026
- Financial Health 70
- Profitability 95
- Business Quality 75
- Balance Sheet 55
- Cash Flow 80
Why this rating?
Health 80/100 — Elite Quality
Timing looks favorable across trend, momentum, valuation, support, and catalysts.
Company overview
Innoviva, Inc. (INVA) is a Biotechnology company in the Healthcare sector. Compound Radar rates Innoviva, Inc. 80/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 4.89
- Forward P/E 9.48
- PEG 3.15
- EV/Revenue 2.89
Profitability
- Revenue Growth 19.3%
- Gross Margin 72.7%
- Operating Margin 43.3%
- Net Margin 81.2%
- ROE 36.7%
Financial strength
- Cash $579.06M
- Debt $331.24M
- Net Cash $247.82M
- Free Cash Flow $186.43M
- Current Ratio 16.01
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$17.04 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$113.31 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- ADMA Biologics, Inc. Biotechnology ADMA$11.06 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$226.79 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$128.01 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$517.49 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$37.95 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Innoviva, Inc. (INVA).